Introduction
Microcystic adnexal carcinoma (MAC) is a rare, indolent, low-grade, malignant cutaneous neoplasm believed to arise from the sweat glands most commonly seen in the head and neck area. 1, 2 Since MAC was first described as a distinct histologic entity in 1982, 3 less than 700 cases have been reported worldwide. MAC typically affects middle aged to elderly whites. MAC lesions usually present as a solitary, slow-growing 1-to 3-cm white yellowish papule or plaque located primarily over the face. 1, [4] [5] [6] Patients are generally asymptomatic and may present years after initial development of the skin lesion. 7, 8 Some develop ulceration or paresthesia if there is perineural invasion (PNI). 5, 9 Despite its subtle clinical appearance, MAC is a locally aggressive and infiltrative tumor and commonly presents with extensive subclinical involvement and PNI, 4, 6, 10 although lymph node involvement and distant metastasis are rare. 2 Given its rarity, research on MAC management is limited to case reports and small retrospective studies. MAC is routinely treated surgically by wide local excision and Mohs micrographic surgery. 11 However, owing to its deeply invasive nature, MAC often requires extensive surgical resection resulting in large anatomic defects in the head and neck region. 12, 13 For patients with large lesions, PNI, and extension to muscle and bone, obtaining clear margins may not be technically feasible or patients may not want to undergo the poor cosmetic and functional consequences. In these cases, there are reports outlining a potential role for radiation (RT) in the adjuvant and definitive setting. 1, 5, 7, 8, 10, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The role of chemotherapy is unclear, as there are only a few cases reported with mixed results. 17, 21, 25, 30 Additional investigation into nonsurgical treatment modalities Sources of support: No external funding was received for this manuscript.
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Case Presentation
A 73-year-old man with a 12-year history of a biopsyproven MAC nodule on his philtrum presented with worsening upper lip numbness, midfacial swelling, and nose firmness over 1 year. He had previously declined surgical resection at his local hospital for this nodule. On our initial examination, he was noted to have a 1 cm exophytic smooth nodule on the philtrum with induration and deformity of upper lip and anterior dorsal nose extending to bilateral cheeks ( Fig. 1 A) . Biopsy of the upper lip lesion confirmed MAC without any PNI or lymphovascular invasion. Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) demonstrated 2 fluorodeoxyglucose-(FDG) avid lesions: a 5.5-cm soft tissue thickening extending from the upper frenulum to the nose and a 2.5-cm submandibular mass ( Fig. 2 A) . There was no bony involvement or distant metastasis. Biopsy of the submandibular mass revealed a low-grade oncocytic neoplasm with hyalinization.
The patient declined surgery and his multidisciplinary care team agreed that surgery would result in significant facial reconstruction with cosmetic and functional deficits given his extensive MAC involvement. Given the long untreated history of this nodule, we recommended definitive RT to the primary site and nodal area with concurrent chemotherapy as a potential radiosensitizer to enhance the efficacy of the treatment in the setting of a 12-year history of an untreated MAC, Throughout 7 weeks of treatment, he received 70 Gy of intensity modulated RT over 35 fractions to the primary site and 4 cycles of concomitant weekly carboplatin (area under the curve 1.5) and paclitaxel (30 mg/m 2 ; Fig. 3 ). Carboplatin/paclitaxel have activity in the metastatic setting and also act as a radiosensitizer in head and neck cancers. [31] [32] [33] In addition, the patient was not a good candidate for cisplatin given his history of bilateral sensorineural hearing loss requiring hearing aids. The facial lymphatic regions were treated to 63 Gy, and bilateral levels I to II lymph nodes were treated to 56 Gy. Taxol was withheld during the last 2 weeks of treatment owing to severe mucositis and pain. There were no radiation treatment breaks.
Clinical response of MAC was observed as early as the second week of chemoRT where he was noted to have reduced facial firmness and deformity. At his 3month visit, PET/CT showed interval decrease in the FDG-avidity and size of the nasal and upper lip lesion, with a focal intense uptake in upper lip correlating with superficial ulceration noted on physical examination likely representing treatment effect ( Fig. 2 B) . MRI showed a slight reduction in tumor thickness. Follow-up scans 6 months after treatment demonstrated a continued decrease in FDG-avidity ( Fig. 2 C) . One year after chemoRT, firmness in his philtrum was confined to 1 Â 1 cm at midline ( Fig. 1 B) , and PET/CT did not demonstrate any FDG avidity or lesions at the site of the primary (Fig. 2 D) . MRI showed stable soft tissue thickening of the upper frenulum and nose. The patient remains asymptomatic and progression-free 6 years from the completion of his treatment.
Discussion
MAC is typically treated surgically by wide local excision or Mohs micrographic surgery. 11 However, definitive surgery is not an option for patients who refuse it or are poor surgical candidates for reasons including competing comorbidities, large expected surgical defects, and inability to achieve negative margins owing to tumor location, PNI, and deep infiltration. In such cases, adjuvant or definitive RT have been used and demonstrated (Table 1) . 5, 7, 8, 10, 12, 14, 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] 27, 29, 30 Chemotherapy has been used in only 4 reported cases showing mixed outcomes. 17, 21, 25, 30 Here, we report a case of an extensive, locally advanced MAC treated by definitive chemoRT resulting in an excellent tumor response and durable disease control.
Our experience builds on previous data showing the efficacy of RT in MAC. In Table 1 , 1,5,7,8,10,12,14-30 we summarize cases of MAC treated by definitive or adjuvant RT. Although interpretation of these studies is limited by the varying clinical situations and heterogeneous RT regimens used, most suggest that RT is effective among cases with high-risk features and may be beneficial even in the definitive setting as a surgical alternative. In a retrospective study by Baxi et al, 10 14 cases treated with local excision and adjuvant RT (median 55 Gy) achieved 17, 21, 25, 30 of chemotherapy used to treat it ( Table 2) . Bier-Laning et al 25 n/a n/a n/a NED at 26 mo (continued on next page) Haga et al 30 recently reported a case using a combination chemotherapy S-1 (tegafur/gimeracil/oteracil) for a locally invasive recurrent tumor of the philtrum previously treated by resection and RT (60 Gy). Objective partial response of the tumor was seen at 8 weeks and the tumor was controlled at 15-month follow-up. To our knowledge, this is the first case of a patient with MAC treated without surgery with definitive chemoRT. Although prophylactic regional nodal irradiation is not standard treatment given its toxicity and rare nodal metastasis of MAC, 10 regional nodes were irradiated in this case to maximize locoregional control given the untreated MAC that had progressed to an extensive involvement of the midface. In addition to RT, we chose to incorporate concurrent chemotherapy given the possibility that RT alone may not be able to sufficiently cure his extensive disease and that chemotherapy could potentially act as a radiosensitizer to improve local control. Using RT with 70 Gy and concomitant paclitaxel/ carboplatin, clinical improvement, and radiographic partial response was achieved within 2 weeks and 3 months of chemoRT, respectively. The patient remains asymptomatic and progression free for about 6 years, which is the longest follow-up reported on MAC tumor control achieved with either RT or chemotherapy. Although our patient did experience significant mucositis and was transiently G-tube dependent, he recovered within 1 month after completion of his treatment and the toxicities are consistent with those expected for a patient treated with chemoRT for a head and neck cancer. Overall, he had an excellent cosmetic result and was able to avoid surgery. Given the retrospective review of our case, it is uncertain whether his tumor would have responded to monotherapy with RT or chemotherapy alone. However, our experience suggests that chemoRT is a tolerable and potentially effective therapeutic modality for locally advanced MAC. ChemoRT in the definitive setting could be considered for patients with inoperable MAC lesions.
